Umbilical cord-derived mesenchymal stromal cells in cardiovascular disease: review of preclinical and clinical data.
acute coronary syndrome
angiogenesis
dilated cardiomyopathy
inflammation
ischaemic cardiomyopathy
mesenchymal stromal cells
regeneration
umbilical cord
Journal
Cytotherapy
ISSN: 1477-2566
Titre abrégé: Cytotherapy
Pays: England
ID NLM: 100895309
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
07
11
2018
revised:
10
04
2019
accepted:
15
04
2019
pubmed:
22
9
2019
medline:
6
6
2020
entrez:
22
9
2019
Statut:
ppublish
Résumé
The human umbilical cord has recently emerged as an attractive potential source of mesenchymal stromal cells (MSCs) to be adopted for use in regenerative medicine. Umbilical cord MSCs (UC-MSCs) not only share the same features of all MSCs such as multi-lineage differentiation, paracrine functions and immunomodulatory properties, they also have additional advantages, such as no need for bone marrow aspiration and higher self-renewal capacities. They can be isolated from various compartments of the umbilical cord (UC) and can be used for autologous or allogeneic purposes. In the past decade, they have been adopted in cardiovascular disease and have shown promising results mainly due to their pro-angiogenic and anti-inflammatory properties. This review offers an overview of the biological properties of UC-MSCs describing available pre-clinical and clinical data with respect to their potential therapeutic use in cardiovascular regeneration, with current challenges and future directions discussed.
Identifiants
pubmed: 31540804
pii: S1465-3249(19)30462-1
doi: 10.1016/j.jcyt.2019.04.056
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1007-1018Subventions
Organisme : Department of Health
ID : DRF-2014-07-008
Pays : United Kingdom
Informations de copyright
Copyright © 2019 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.